Aperture Bio, Inc.

Aperture Bio, Inc. is a woman-owned small business located in Cambridge, Massachusetts, focused on developing advanced imaging and molecular analysis technologies for precision medicine applications. Registered in the System for Award Management (SAM.gov) with a current registration valid through June 18, 2026, the company specializes in creating innovative diagnostic and research platforms that enable sophisticated cellular analysis, particularly in oncology and cell therapy domains.

The company has secured multiple federal grant awards from the National Cancer Institute (NCI), totaling approximately $805,000, to develop and validate cutting-edge single-cell proteomic profiling technologies. These grants specifically support the development of a cyclic immunofluorescent imaging platform designed to improve precision medicine approaches by enabling dynamic measurement of complex cellular functions and biological processes in live cells. The first grant, awarded on March 1, 2025, for $404,994, focuses on developing and assessing the feasibility of their imaging platform for preclinical applications in drug development, cell therapy manufacturing, regenerative medicine, and oncology research. A subsequent grant, awarded on May 20, 2024, aims to commercialize a platform for rapid molecular analysis of minute and fragile cell populations, with the goal of generating precise protein expression, cell state, and co-localization data. These projects address significant clinical challenges, such as understanding treatment resistance in cancer and developing more accurate diagnostic tools for selecting optimal therapeutic interventions.